IPO Verve Therapeutics (economic model)

Ticker: VERV

Develops one-year treatments for cardiovascular disease using gene editing.

Revenue

Missing

Profit

While losses

Express withdrawal

A classic pharmaceutical company with a potential drug discovery.

Debts

0,1 debt / equity, at a rate of less than 2

Excellent indicator

Financial calculation

There is nothing to evaluate without revenue.

There is no fair share price.

IPO range: $16 -18.

I do not participate, because. the company has no revenue.